An interventional study of INTEGREAT-CKD Intervention in Chronic Kidney Diseases, sponsored by Alexandra Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Alexandra Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency, Chronic with a site in Singapore — 5 open to participants now, 9 under way, 5 of them phase 3. Renal Insufficiency, Chronic · Singapore.
Among the 32 studies in Renal Insufficiency, Chronic with a site in Singapore, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 with no phase, and was the 28th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 32 studies in Renal Insufficiency, Chronic with a site in Singapore are open now. Recruiting first, the newest first:
Singapore Institute of Technology · Sites in Singapore
Ages 21+
AstraZeneca · Sites in Singapore, United States, Argentina and 39 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Singapore, United States, Argentina and 33 more countries
Ages 18–100
Amgen · Sites in Singapore, United States, Argentina and 7 more countries
Ages 0–18
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 15 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 540 across the 25 interventional studies, 500 across the 6 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 32 have an industry lead sponsor. The 10 most frequent:
Alexandra Hospital is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Alexandra Hospital has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency, Chronic with a site in Singapore that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT07804316Singapore Institute of TechnologyFostering Self-Empowerment in CKD Patients Through Food Choice Mapping | 2027-01-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency, Chronic with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic kidney disease (CKD) is a prevalent chronic disease and is often intertwined with the management of cardiovascular disease and the optimization of metabolic risk factors. In light of steeply rising rates of end-stage kidney disease (ESKD) and increased healthcare resource utilization by CKD patients, the investigators propose that the role of nurses could be expanded to support the care of CKD patients in the community.
A total of 220 patients will be randomized (1:1) to the intervention or control groups (usual care). The intervention entails enrolment into a nurse-led, physician-supported programme (INTEGREAT-CKD), comprising outpatient consultations and community-based ambulatory monitoring and counselling primarily driven by CKD-trained advanced practice nurses (APNs) and healthcare professionals conducted over 6 months. Patient-reported outcomes like health-related quality of life (HRQOL), as measured by EQ-5D and KDQOL, CKD self-management score and CKD health literacy will be assessed at baseline and after 6 months. The primary outcome is CKD self-management. Other secondary outcomes to be assessed and tracked including achievement of clinical targets relevant to slowing down CKD progression, attainment of CKD best practice guidelines as specified in the KDIGO CKD Evaluation and Management guidelines 2020.
Study objectives:
Study design This study is a dual-centre two-arm, open-label randomized controlled trial (RCT). Patients are randomized with a one-to-one allocation into two parallel groups. Participants with advanced CKD referred to the tertiary institutions are randomized to either the control group (physician-led standard of care consultation model) or the experimental (intervention) group, which consists of enrolment in the INTEGREAT-CKD programme. INTEGREAT-CKD is a six-month programme consisting of an outpatient nurse-led consultation model, delivered by a team of CKD-trained Advanced Practice Nurses (APNs) and community-based nurses. Participants are reviewed in person at a 3-monthly interval by a CKD-trained APN independently. The CKD-trained APN's practice is supported by adherence to a protocol-based and algorithmic set of guidelines co-written by the CKD-trained APN and nephrologist for the main clinical aspects of CKD care. Each clinic session is allocated an extended duration of 30 minutes to educate patients on CKD-related medical knowledge, targeted lifestyle modification, and self-management skills. Questionnaires to determine patient's health literacy, self-management skills, and quality of life are assessed at the beginning and end of the study.
Setting:
The study will be conducted across two tertiary hospitals, Alexandra Hospital (AH) and National University Hospital (NUH), located in the western cluster of Singapore. Both hospitals are tertiary healthcare institutions that receive outpatient nephrology consult referrals, including consultation about CKD management, from within the institutions and primary healthcare sector within the western cluster.
Population and Sample:
The investigators plan to implement the envisioned intervention right from when CKD patients are referred to a nephrologist in one of the two institutions. Care received from this point onwards can significantly shape the course of a CKD patient's care journey.
Study Intervention Patients allocated to the intervention group will receive the nurse-led care (INTEGREAT-CKD), which comprises of the following components. Every recruited participant will be reviewed in person by a CKD-trained APN in the clinic on a 3-monthly basis for optimization of the medical management of CKD. Every patient is designated a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The 30-minute timeslot starts with a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management. The subsequent 15-minute time slot will be dedicated to educating patients on improving their knowledge of CKD, including the importance of optimizing clinical parameters that influence CKD progression.
Patients will be placed on community-based and monthly monitoring of clinical parameters relevant to CKD progression. Patients will self-report the monitored parameters to a community-based nurse through a telehealth platform.
Clinical parameters that are out of range will be escalated to the CKD-trained APN, who oversees the monitoring of the community-based monitored parameters and titration of appropriate medications.
Control group Patients assigned to the control group receive the usual standard of care at most specialist outpatient clinics in any tertiary restructured hospital in Singapore. They are not routinely scheduled to receive nurse-led CKD care - management by a CKD-trained APN and community-based monitoring of clinical parameters
Recruitment procedure CKD patients in Alexandra Hospital and National University Hospital who fulfill the study's inclusion criteria will be recruited for participation in the study. They may be recruited from the inpatient wards or outpatient clinics by a member of the research team. After providing written consent, the participants will be randomized to the intervention or control groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control arm: Patients will be assigned to a consultation model of CKD care which consists of clinic reviews by a nephrologist, which is as per current standard of care. The frequency of reviews, which is at the discretion of the nephrologist, is typically scheduled at 4 to 6 monthly intervals. Each consultation lasts an average of 10 to 15 minutes.
Intervention arm: Patients will be assigned to a consultation model of CKD care which consists of 30-minute clinic reviews led by an advanced practice nurse (APN), with both on-site and remote support from a nephrologist, at 3 monthly intervals. Patients will be required to monitor certain clinical parameters (one of or a combination of blood pressure, glucose trend or weight trend) between clinic reviews, tapping on a telehealth platform for transmission of data to an assigned community-based nurse, who will provide oversight of these readings, with regular escalation to the APN/nephrologist. The on-site remote support, in the form of telehealth monitoring, will be concurrent between clinic consults, with frequency of monitoring individualized as per patient's needs.
Other: INTEGREAT-CKD Intervention
The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification. Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status.
Chronic Kidney Disease Self-Management (CKD-SM) Questionnaire
Patients will be scored based on their questionnaire responses and the primary outcome is the improvement in the CKD-SM score. Baseline scoring is done during enrolment.
Time frame: 24 weeks from participants' date of enrollment
Secondary outcome
(a) An achievement of clinical targets relevant to slowing down CKD progression: a. Individualised blood pressure target achieved depending on clinical profile: i. CKD, non-diabetic with proteinuria: \< 140/80mmHg ii. CKD, diabetic with proteinuria: \< 130/80 b. Target glycemia control: HbA1c lower than 8% c. Achievement and maintenance of euvolemia (individualized target weight that reflects euvolemia) (b) CKD best practice guidelines as specified in the KDIGO CKD Evaluation and Management guidelines a. Achievement of target biochemical indices related to optimization of CKD care: i. Mineral bone disease (CKD-MBD) 1. Serum phosphate and serum calcium within normal ranges 2. Serum parathyroid hormone to be maintained at approximately 2-9 times the upper normal limit for the assay{, #282} ii. Anemia 1. Serum haemoglobin 10.5-11.5 g/dL (c) An improvement in the 30-day readmission (d) A reduction in the incidence of emergency department visits
Time frame: 24 weeks from participants' date of enrollment
Plan to share: No
Started Nov 2023 (actual). Primary completion is estimated for May 2025, 18 months after the start.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 18 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Alexandra Hospital